URAC Rare Disease Pharmacy Center of Excellence Certification: Regional Specialty Pharmacy Case Study
Last updated: April 2026
A regional specialty pharmacy with an established rare disease patient population and years of URAC Specialty Pharmacy Accreditation had been losing limited-distribution drug contracts to national competitors. The reason was not clinical — their patient outcomes were strong. The reason was documentation: they could not prove to manufacturers that their rare disease operations met the standard required. IHS guided them through URAC Rare Disease Pharmacy Center of Excellence Certification in eleven months. This is how that engagement unfolded.
Client details are anonymized per IHS confidentiality policy. The operational patterns described are representative of engagements IHS has conducted with regional specialty pharmacies pursuing URAC Rare Disease Pharmacy Center of Excellence Certification.
The Situation: Strong Clinically, Invisible Competitively
The pharmacy had operated a rare disease patient population for six years — primarily hemophilia and lysosomal storage disorder patients — with a multidisciplinary clinical team and clinical outcomes data their medical director described as competitive with any specialty pharmacy in the country. They held URAC Specialty Pharmacy Accreditation and had renewed it successfully through two cycles.
The problem emerged when two manufacturers of newly approved orphan drugs contacted them about their interest in being included in limited-distribution networks. In both cases, the manufacturer's pharmacy partner evaluation process included a question that stopped the conversation: did the pharmacy hold URAC Rare Disease Pharmacy Center of Excellence Certification?
The answer was no. Both manufacturers indicated they were prioritizing pharmacies that held the designation. One contract went to a national specialty pharmacy operator. The other manufacturer placed the pharmacy on a "qualified pending certification" list and gave them eighteen months to earn the credential.
The pharmacy's Chief Pharmacy Officer contacted IHS with a direct question: "We do this work. We just can't prove it in the way URAC requires. How fast can we fix that?"
Phase 1: Gap Analysis — What "We Do This" Actually Looked Like on Paper
The first engagement was a standards gap analysis against all five Rare Disease Certification standards. The pharmacy had strong clinical operations. Their documentation posture was another matter.
What the Gap Analysis Found
Rare Disease-Specific Clinical Assessment: Partial
The pharmacy used a single patient intake and assessment template across all specialty conditions — a common approach in URAC Specialty Pharmacy Accreditation compliance. For Rare Disease Certification, URAC requires clinical assessments tailored to each specific rare or orphan condition. The hemophilia assessment template looked structurally identical to the Gaucher disease assessment template, which looked structurally identical to the general oncology assessment template. The clinical content in the completed records was differentiated by the pharmacists filling them out — but the underlying template structure did not reflect the disease-specific clinical dimensions URAC requires.
Gap severity: Moderate. The clinical knowledge was present. The documentation structure was not.
Disease-Specific Education Programs: Significant Gap
The pharmacy had patient education materials — printed handouts, verbal counseling scripts, and a patient portal with general specialty pharmacy information. For Rare Disease Certification, URAC requires disease-specific education programs for patients, caregivers, providers, and payers. What the pharmacy had was general specialty pharmacy patient education with condition names substituted at the top of the document. The hemophilia patient education brochure and the lysosomal storage disorder patient education brochure had the same structure, the same clinical content blocks, and the same language — only the condition name changed.
Gap severity: Significant. This would not survive URAC review. Disease-specific programs had to be built from the condition up, not templated from a general specialty pharmacy model.
Multidisciplinary Team Collaboration: Undocumented
The pharmacy had a functioning multidisciplinary team. Weekly case conferences included the clinical pharmacist, care coordinator, specialty nurse, and — for complex cases — the treating specialist. The gap was total absence of documentation. No meeting minutes. No case review records in patient files. No documentation of provider communication outcomes. The team was doing the work. Nothing in the files proved it.
Gap severity: Critical. URAC evaluates evidence, not attestation. The work being done in real time was invisible on paper.
Data Collection and Analytics: Partial
The pharmacy tracked general specialty pharmacy performance measures — refill rates, call response times, prescription fill accuracy, patient satisfaction scores — through their pharmacy management system. What they did not have was a rare disease patient population analytics layer: outcomes tracking specific to hemophilia and lysosomal storage disorder patients, adherence patterns by condition, clinical incident rates by rare disease category.
Gap severity: Moderate. The data existed in fragmented form across the pharmacy management system. It had not been organized into a population-level rare disease analytics framework.
Continuous Quality Improvement: Not Rare Disease-Specific
The pharmacy had a CQI program — a well-documented one that had satisfied URAC surveyors through two Specialty Pharmacy Accreditation cycles. The problem was that the CQI program addressed general specialty pharmacy operations. None of the performance measures tracked, none of the improvement cycles documented, and none of the corrective actions recorded were specific to rare disease patient outcomes. URAC requires a CQI program evaluated against rare disease performance measures.
Gap severity: Significant. The CQI infrastructure was sound. The rare disease layer was absent.
IHS Assessment
The gap analysis confirmed the Chief Pharmacy Officer's framing — "we do this work, we just can't prove it" — was accurate for two of the five standards (multidisciplinary team, analytics) and only partially accurate for three (assessment templates, education programs, CQI). The clinical capability was real. But URAC does not evaluate clinical capability in the abstract. It evaluates documented operational compliance with specific standards. Two of the five standards required building documentation infrastructure around existing practice. Three required building or substantially rebuilding the practices themselves.
IHS delivered a remediation roadmap with three priority tiers, timelines for each standard, and a recommendation to pursue the eighteen-month manufacturer deadline rather than an accelerated submission — giving the pharmacy adequate operational evidence-generation time before the survey date.
Phase 2: Remediation — Building Documentation to Match Clinical Reality
Rare Disease-Specific Clinical Assessment Templates
IHS worked with the pharmacy's clinical pharmacists to develop disease-specific assessment frameworks for each condition in their drug portfolio. For hemophilia: factor product type, inhibitor status, bleeding phenotype, joint health history, infusion site assessment, adherence to prophylaxis schedule, and psychosocial assessment dimensions specific to the chronic, often pediatric, hemophilia patient experience. For lysosomal storage disorders: enzyme replacement therapy infusion history, substrate accumulation indicators, organ system involvement by disease variant, caregiver burden assessment, and transition of care planning for adult patients.
The frameworks were built from the clinical dimensions of each condition — not from a general template with condition names inserted. IHS provided the structural framework; the pharmacy's clinical team contributed the disease-specific clinical content. The result was assessment documentation that reflected what the clinical team was already evaluating in practice, organized in a structure URAC surveyors would recognize as disease-specific.
Disease-Specific Education Programs
This was the most labor-intensive remediation element. IHS provided frameworks for building condition-specific education programs — covering the structural requirements (patient, caregiver, provider, and payer education components; disease-specific clinical content; documentation of program delivery and patient comprehension) and the content architecture. The pharmacy's clinical team built condition-specific content for hemophilia and lysosomal storage disorder patient populations.
The hemophilia education program addressed home infusion technique, bleeding episode recognition and response, joint protection, activity modification, school and workplace communication, emergency identification, and adherence strategies specific to factor replacement regimens. The lysosomal storage disorder program addressed infusion preparation and site care, infusion reaction recognition, symptom monitoring by organ system, genetic counseling access, insurance authorization navigation, and condition-specific caregiver support resources. Neither program shared content blocks with the other beyond basic pharmacy contact information.
IHS reviewed drafts against the URAC standard to confirm the disease specificity would satisfy the surveyors' evaluation criteria before the clinical team invested final production time.
Multidisciplinary Team Documentation
The fix here was structural, not clinical — the team was functioning, it just was not generating records. IHS designed a documentation framework for weekly case conferences: a standardized case review record that captured patients discussed, clinical issues raised by each discipline, care plan modifications, provider communications initiated or received, and action items assigned with follow-up dates. The framework was integrated into the pharmacy's existing patient management system so documentation occurred as part of the clinical workflow, not as a separate administrative burden.
Each patient file received a communication log section where provider interactions — inbound and outbound — were recorded with date, party, content summary, and outcome. Within three months of implementation, the pharmacy had a patient file structure that documented what the multidisciplinary team had been doing all along.
Rare Disease Analytics Framework
IHS worked with the pharmacy's IT team to build a reporting layer within their existing pharmacy management system that organized outcomes data by rare disease patient population. Key metrics established: adherence rates by condition and patient cohort, clinical incident rates (bleeding episodes for hemophilia patients, infusion reactions for enzyme replacement therapy patients), care transitions documented (emergency department encounters, hospitalizations, care setting changes), refill adherence by condition, and patient satisfaction scores disaggregated by rare disease category.
The analytics framework generated quarterly population-level reports for each rare disease category — providing the data collection and analytics documentation URAC requires and simultaneously giving the pharmacy's medical director visibility into population-level performance that had previously existed only in aggregate specialty pharmacy metrics.
Rare Disease CQI Program Integration
IHS redesigned the pharmacy's CQI program to incorporate rare disease-specific performance measures alongside the existing general specialty pharmacy measures. Three rare disease performance measure cycles were established for the pre-survey period: one addressing hemophilia patient adherence to prophylaxis regimens with root cause analysis of non-adherence and intervention design; one addressing lysosomal storage disorder infusion reaction rates with protocol review and staff competency assessment; and one addressing rare disease care transition documentation completeness.
Each cycle followed the standard CQI structure — measure, analyze, improve, re-measure — with documentation of the full cycle in the CQI program records. By the survey date, the pharmacy had three complete rare disease CQI cycles with documented improvement activity, giving URAC surveyors the evidence of an operating CQI program evaluated against rare disease outcomes.
Phase 3: Mock Review — What the Files Actually Said
Eight months into the engagement, IHS conducted a mock review of ten patient files — five hemophilia, five lysosomal storage disorder — auditing each against the five Rare Disease standards plus the nine Specialty Pharmacy Accreditation modules. The mock review identified three issues that would have generated RFIs in a live URAC survey.
Issue 1: Multidisciplinary Documentation Inconsistency
Four of ten patient files had complete case conference records. Three had case conference records with incomplete action item follow-up documentation. Three had case conference records that noted a patient was discussed but did not capture discipline-specific input from each team member. URAC surveyors would score the incomplete records as partial compliance — insufficient for certification.
Resolution: IHS provided specific guidance on the documentation completeness requirements for each team member's contribution to case conference records. The clinical team conducted a targeted documentation training session. A file review three weeks later confirmed the pattern was corrected.
Issue 2: Education Program Delivery Documentation Gaps
The disease-specific education programs existed and were clinically appropriate. What was missing in five of ten files was documentation that the program had been delivered — the patient or caregiver interaction record showing what education was provided, when, by whom, and the patient's demonstrated comprehension. The programs had been delivered. The delivery had not been consistently documented.
Resolution: IHS designed a structured education delivery checklist integrated into the patient encounter record — capturing program delivery, patient/caregiver response, and comprehension confirmation. Implementation required a single workflow change for clinical pharmacists conducting patient counseling sessions.
Issue 3: Caregiver Education Component Incomplete
The hemophilia education program had robust patient content and provider content but thin caregiver content — a gap that reflected the fact that most of the pharmacy's hemophilia patients were adults managing their own care. For pediatric hemophilia patients, the caregiver content was insufficient for URAC's standard. IHS flagged this as a targeted gap requiring additional content development for the pediatric patient subset.
Resolution: The pharmacy's clinical team developed a caregiver-specific hemophilia education module addressing home infusion technique for caregivers, bleeding episode response, school and camp communication, and emergency protocol for pediatric patients. The module was integrated into the education program documentation and applied retroactively to files for pediatric patients.
Mock Review Outcome
After the three issues were corrected, IHS conducted a second file review on the same ten patient files. All ten passed the five Rare Disease standards without deficiency. IHS confirmed readiness for submission.
Outcome: Certification and Manufacturer Network Access
The pharmacy submitted its Rare Disease Certification application eleven months after the IHS engagement began. URAC conducted the survey review and issued no Requests for Information — the file documentation, program documentation, analytics reports, and CQI records satisfied all five Rare Disease standards and all nine Specialty Pharmacy Accreditation modules without deficiency findings requiring response.
URAC awarded the Rare Disease Pharmacy Center of Excellence Certification within the standard decision timeline. The pharmacy joined approximately 23 specialty pharmacies in the United States holding the designation.
What Certification Made Possible
Within four months of receiving certification:
- The manufacturer who had placed them on the "qualified pending certification" list executed the limited-distribution agreement. The pharmacy gained access to the orphan drug they had been excluded from for eighteen months.
- A second manufacturer conducting a network review for a new rare disease therapy included the pharmacy in their evaluation pool as a result of the certification — a conversation that had not been available to them prior to earning the designation.
- The pharmacy's rare disease referral pipeline from treating specialists increased as the certification became part of their market communications. Specialists routing rare disease patients to specialty pharmacies began directing patients to them explicitly on the basis of the URAC designation.
What Changed Internally
The clinical team reported that the documentation infrastructure built for certification improved their own situational awareness of the rare disease patient population. The rare disease analytics framework — built to satisfy URAC's data collection standard — gave the medical director population-level visibility that had not previously existed in a reportable format. The multidisciplinary team documentation framework made the case conference process more structured and the action item follow-through more consistent.
The Chief Pharmacy Officer's assessment six months after certification: "The certification told us we had gaps we didn't know about. Fixing them made us better at the clinical work we thought we were already doing well."
What This Engagement Illustrates
This engagement reflects patterns IHS sees consistently in specialty pharmacies pursuing URAC Rare Disease Pharmacy Center of Excellence Certification.
Clinical performance and documentation compliance are not the same thing
The pharmacy was clinically strong. Their patient outcomes were competitive. Their multidisciplinary team was functioning. None of that was visible to URAC surveyors — or to the manufacturers evaluating them — because the clinical performance was not documented in the structure URAC's standards require. The gap analysis revealed the distance between "we do this" and "we can prove we do this to URAC's standard." These are different things, and closing the gap requires work that is structural and operational, not clinical.
Generic specialty pharmacy processes do not satisfy rare disease standards
The single assessment template applied across all conditions, the general specialty pharmacy education materials with condition names substituted, and the general CQI program without rare disease measures — these were adequate for URAC Specialty Pharmacy Accreditation. They were not adequate for Rare Disease Certification. The Rare Disease standards require disease-specific construction, not general specialty pharmacy templates applied to rare disease patients. This distinction is the most common source of failed or deficient Rare Disease applications.
Documentation infrastructure built for compliance becomes a clinical asset
Every documentation system built for this engagement — the disease-specific assessment templates, the multidisciplinary team records, the rare disease analytics framework, the education program delivery documentation — continued serving the pharmacy's clinical operations after the survey concluded. Compliance documentation and clinical documentation are not separate systems. Building them correctly for URAC creates infrastructure that makes the clinical team's work more visible, more measurable, and more improvable.
The eighteen-month manufacturer deadline was achievable — barely
Eleven months from engagement start to application submission with three months remaining in the manufacturer's window. The timeline worked because the pharmacy had strong clinical foundations and a committed clinical team that integrated documentation changes into workflow quickly. A pharmacy starting from weaker operational foundations — particularly weaker existing Specialty Pharmacy Accreditation compliance — would have needed more time. IHS's consistent guidance: pursue Rare Disease Certification before the manufacturer deadline is on the table, not in response to it.
Schedule a Free Discovery Session
If your pharmacy dispenses rare or orphan medications, IHS offers a complimentary discovery session to assess your current accreditation posture, evaluate your eligibility for URAC Rare Disease Pharmacy Center of Excellence Certification, and identify the gap between where your documentation is today and what URAC requires. Thomas G. Goddard, JD, PhD, former Chief Operating Officer and General Counsel of URAC, leads all URAC engagements.